Marshall Wace’s Belite Bio BLTE Stock Holding History

Marshall Wace’s Portfolio BLTE Stock Details BLTE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$15.3M	Buy	+89,988	New	+$14.6M	0.01%	799
2026 Q1	–	Sell	-192,700	Closed	-$30.8M	–	3208
2025 Q4	$30.8M	Buy	192,700 +5,200	+3%	+$616K	0.03%	484
2025 Q3	$13.9M	Buy	187,500 +178,014	+1,877%	+$11.7M	0.01%	803
2025 Q2	$547K	Buy	+9,486	New	+$579K	﹤0.01%	2115
2025 Q1	–	Sell	-5,865	Closed	-$370K	–	2636
2024 Q4	$370K	Sell	5,865 -2,621	-31%	-$173K	﹤0.01%	2163
2024 Q3	$398K	Buy	+8,486	New	+$411K	﹤0.01%	2002
2024 Q2	–	Sell	-10,584	Closed	-$406K	–	2565
2024 Q1	$406K	Sell	10,584 -5,427	-34%	-$243K	﹤0.01%	2010
2023 Q4	$733K	Buy	+16,011	New	+$615K	﹤0.01%	1584

Other funds holding BLTE

Eventide Asset Management Boston, Massachusetts $7.14B AUM 65.02% 1-Year Est. Return

Neuberger Berman Group New York $148B AUM 31.56% 1-Year Est. Return

Affinity Asset Advisors New York $2.46B AUM 196.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Patient Square Capital Menlo Park, California $627M AUM 115.4% 1-Year Est. Return

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return

NWI Management New York $2.67B AUM 61.94% 1-Year Est. Return

Walleye Capital New York $109B AUM 29.28% 1-Year Est. Return

Marshall Wace's BLTE Position: Q3 2026 in Review

Marshall Wace opened a new position in Belite Bio (BLTE) in Q3 2026: 89,988 shares worth $15.3M. The stake represents 0.01% of the portfolio and ranks #799 among its holdings. This is a return to the name: Marshall Wace previously reported a position in BLTE as recently as Q4 2025.

Marshall Wace first reported a position in BLTE in Q4 2023 and has held it in 8 quarters since. The position peaked at $30.8M in Q4 2025. 54 funds tracked by Wall St. Rank hold BLTE as of Q3 2026.

Marshall Wace held 89,988 shares of Belite Bio worth $15.3M as of Q3 2026.
Belite Bio was a new Marshall Wace position in Q3 2026.
Belite Bio made up 0.01% of Marshall Wace's portfolio in Q3 2026, its #799 holding.
Marshall Wace first reported a position in Belite Bio in Q4 2023 and has held it in 8 quarters since.
Marshall Wace's Belite Bio position peaked at $30.8M in Q4 2025.
54 funds tracked by Wall St. Rank held Belite Bio as of Q3 2026.

Based on Marshall Wace's 13F filing for Q3 2026, filed 13 Nov 2026.